Compare Crispr Therapeutics AG (CRSP) vs Vanguard Real Estate Index Fund ETF (VNQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Vanguard Real Estate Index Fund ETF — how do they compare? Crispr Therapeutics AG trades at $53.77 (market cap $4.88B), while Vanguard Real Estate Index Fund ETF trades at $90.47 (market cap $70.80B). The key difference: Vanguard Real Estate Index Fund ETF is far larger — about 14.5× Crispr Therapeutics AG's market cap, and Vanguard Real Estate Index Fund ETF is more actively traded (6,073,580 versus 2,861,747). Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Vanguard Real Estate Index Fund ETF for 113 Days on average.
| CRSP | VNQ | |
|---|---|---|
Market Cap | $4.88B | $70.80B |
Volume | 2,861,747 | 6,073,580 |
Sector | Health | — |
52-Week High | $74.92 | $100.95 |
52-Week Low | $44.34 | $87.00 |
Typical Hold Time | 77 Days | 113 Days |
Enterprise Value | $3.30B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.41, up 2.02% with a bearish technical signal despite recent earnings beats. The company shows negative profitability metrics with -$581.60M net income in 2025 and revenue volatility, though analyst consensus remains bullish with a $67.83 price target. Key catalysts include upcoming clinical data presentations for autoimmune disease therapies and CASGEVY commercialization progress.
The stock presents high-risk, high-reward potential with strong Wall Street support (57.9% buy ratings) but faces significant execution risks. Near-term performance hinges on clinical trial outcomes and revenue generation from approved therapies, while persistent cash burn and competitive pressures remain key concerns for investors.
VNQ trades at $90.50, up 2.04% today but facing a bearish technical trend with key support at $87. The ETF's fundamentals are obscured by missing valuation ratios, while sentiment is mixed amid rising interest rates pressuring REIT yields. Recent news highlights institutional buying but also concerns over dividend sustainability versus Treasury bills.
Outlook remains cautious due to interest rate sensitivity and sector oversupply risks. Opportunities exist for contrarian investors seeking long-term real estate exposure, but near-term headwinds from Fed policy and economic volatility warrant careful risk assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Vanguard Real Estate Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Real Estate 25/50 Index, an index made up of stocks of large, mid-size, and small US companies within the real estate sector. The Advisor attempts to replicate the target index by seeking to invest all of its assets in the stocks that make up the index, in order to hold each stock in approximately the same proportion as its weighting in the index. It is non-diversified.
Read more on VNQ →
